share_log

Wells Fargo Maintains Overweight on Blueprint Medicines, Lowers Price Target to $151

Wells Fargo Maintains Overweight on Blueprint Medicines, Lowers Price Target to $151

富国银行仍然看好blueprint medicines,将目标价格下调至151美元
Benzinga ·  11/01 03:46  · 评级/大行评级

Wells Fargo analyst Derek Archila maintains Blueprint Medicines (NASDAQ:BPMC) with a Overweight and lowers the price target from $153 to $151.

Wells Fargo分析师Derek Archila维持Blueprint Medicines(纳斯达克:BPMC)的股票评级为超配,并将价格目标从153美元下调至151美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发